Now PlayingEP. 1 Clinical Case Presentation: A 36-Year-Old Woman with Breast Cancer and Brain Metastases
EP. 6 Clinical Case Presentation: A 53-Year-Old Woman with Metastatic ER/PR+ HER2+ Breast Cancer and Brain Metastases
EP. 10 Clinical Case Presentation: A 66-Year-Old Woman with ER+ HER2+ Invasive Ductal Carcinoma and Brain Metastases
November 19th, 2026ET Adherence Raises Cardiometabolic Risk, Improves Survival in HR+ Breast CancerFive-year AI adherence was tied to more hypertension, dyslipidemia, and diabetes in HR+ breast cancer, yet adherence also lowered all-cause mortality.Read more
November 16th, 2026FDA Approves Giredestrant/Everolimus for ER+, HER2–, ESR1-Mutated Breast CancerThe FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated breast cancer based on data from the phase 3 evERA trial.Read more
November 16th, 2026FDA Approves Pertuzumab Biosimilar in HER2+ Breast CancerThe FDA has approved pertuzumab-qcay, a biosimilar of the reference product Perjeta, in HER2-positive breast cancer, based on a data package that showed no meaningful differences in quality, safety, efficacy, or immunogenicity.Read more
November 12th, 2026Anthracycline Chemo May Accelerate Biological Aging in Breast Cancer SurvivorsModel data suggest anthracycline-based chemotherapy may cost breast cancer survivors a median of 9.4 life-years through biological age acceleration.Read more
November 10th, 2026FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutant HR+/HER2– Breast CancerThe FDA set a June 25, 2027, PDUFA date for gedatolisib in PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy.Read more